SET AND READY TO UNLEASH THE POTENTIAL OF THE PHARMACIST HEALTH WORKFORCE Government aligns Scope of Practice review with Pharmacists in 2030 report
Filmed in Perth, Western Australia, November 2024
With Associate Professor Fei Sim, National President
Pharmaceutical Society of Australia (PSA)
Last week, Associate Professor Fei Sim the National President of the Pharmaceutical Society of Australia (PSA), the peak body representing 39,000 pharmacists across Australia’s health system, spoke to Australian Health Journal about the release of the Unleashing the Potential of our Health Workforce – Scope of Practice Review. The review and final report sets out to create a clear pathway for health professionals to contribute more to our health system and practice to their full and top of scope.
The report calls for governments to remove the inconsistent barriers that restrict the scope of healthcare professionals, including pharmacists.
PSA National President Associate Professor Fei Sim FPS commended the report’s focus on removing barriers for pharmacists and other healthcare professionals as a critical step towards a more accessible and resilient healthcare system.
“This review confirms PSA’s view that inconsistent regulations, unnecessary restrictions on practice, and siloed workforces are having a negative impact on patient access to quality health care,” Associate Professor Sim said.
“Pharmacists are some of the most accessible healthcare professionals in our communities, yet regulatory barriers continue to limit our ability to provide care when and where our patients need it. The release of this final report is the next step towards breaking down these barriers through a short- and long-term reform agenda, addressing the inefficiencies in our health system.”
Associate Professor Sim said that the report’s recommendations present a genuine opportunity to improve access to health care across Australia.
“There is a clear alignment between Cormack’s recommendations and the actions in PSA’s vision for the pharmacy profession, Pharmacists in 2030. Both present a clear vision for the future that requires collaboration for a health system that works for patients,” Associate Professor Sim said.
“This report recognises the core role of pharmacies and pharmacists as primary healthcare providers and recommends a multidisciplinary approach to patient care.
“In order to make the most of the opportunities presented by the report, we need governments, regulators and health care professionals to work together for a strong, sustainable health system that utilises all health professionals to their full scope.
“I urge governments and stakeholders at all levels to accept and act on the report’s recommendations in full to build a health system ready for the growing health needs of Australians.”
A/Prof Fei Sim served on the Cormack Review’s Expert Advisory Committee, representing the pharmacy profession.
-
Taiwanese health and research delegation visit Paratus clinical trial site in Canberra
In late August 2025, a Taiwanese delegation comprising government officials from the Taiwanese FDA, various governmental groups, and physicians and researchers from across Taiwan, visited Paratus Clinical’s trial site in Canberra. Their objective was to explore both the differences and similarities between the clinical research ecosystems of Taiwan and Australia.
-
Budget22 A mixed dose of health outcomes
Australian Health Journal met with a number of industry heads after the budget on their journeys so far in lobbying for change, their achievements, some of the disappointments and their thoughts on the road ahead, with an election round the corner.
-
Mission to raise awareness of sarcoma and need for clinical trial funding
Sarcoma, a rare and aggressive cancer, remains the deadliest cancer for children and young adults, accounting for nearly one third (30%) of cancer-related deaths among those aged 15–24 and one tenth (10%) of those aged 0–14. Further, still severely under-diagnosed, sarcoma only accounts for one sixth (15%) of all cancer diagnoses in the 15 – 24 age group, and less than a tenth (8%) among children under 10.
